SujanaMovvaMD

Oncology • New York, NY

Hematologic Oncology, Melanoma, Sarcoma

Fox Chase Cancer Center

Join to view full profile

Dr. Movva is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Movva's full profile

Already have an account?

Office
1275 York Ave
New York, NY 10065
Phone+1 646-888-4342

Education & Training

University of Western OntarioClass of 2003
McLaren Health Care/Flint/MSUResidency, Internal Medicine

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2018 - 2026
CT State Medical License 2023 - 2025
NJ State Medical License 2018 - 2025
NC State Medical License 2020 - 2022
PA State Medical License 2012 - 2018
GA State Medical License 2010 - 2013
NM State Medical License 2007 - 2010
MI State Medical License 2004 - 2007
American Board of Internal Medicine Medical Oncology
Join now to see all

Clinical Trials

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Jan 24
Active, not recruiting
Phase 2
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis Start of enrollment: 2014 Mar 21
Completed
Phase 3
A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma Start of enrollment: 2016 Mar 01
Completed
Phase 1, Phase 2
Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas Start of enrollment: 2017 Feb 21
Terminated
Phase 2
Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) Start of enrollment: 2017 Aug 08
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

54 citations
Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen
Claire F. Verschraegen, Hugo Arias-Pulido, Sang Joon Lee, Sujana Movva, Lisa A. Cerilli
Annals of Oncology. 2012-03-01
104 citations
Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab
Emily Z. Keung, Melissa Amber Burgess, Ruth Salazar, Edwin R. Parra, Jaime Rodrigues-Canales
Clinical Cancer Research. 2020-03-15
251 citations
Sorafenib for Advanced and Refractory Desmoid Tumors.
Mrinal M. Gounder, Michelle R. Mahoney, Brian A. Van Tine, Vinod Ravi, Steven Attia
The New England Journal of Medicine. 2018-12-20

Press Mentions

Overall Survival Benefit for Patients with Stage III Soft Tissue SarcomasMay 30th, 2014